To date, two systemic small-molecule CFTR modulators have been evaluated in pivotal clinical trials in individuals with CF and specific mutant CFTR genotypes that have led to regulatory review and/or ...

Exposure to elexacaftor-tezacaftor-ivacaftor (ETI) is associated with metabolic syndrome (MetSyn) in patients with cystic fibrosis.